Skip to main content
. 2022 Mar 15;43(10):2636–2650. doi: 10.1038/s41401-022-00889-4

Fig. 9. Schematic diagram of the effect of SGLT2 inhibitor sotagliflozin on facilitating therapeutic angiogenesis in diabetic HLI mice.

Fig. 9

Sotagliflozin promotes the viability, proliferation, and migration potentials of skeletal muscle cells, and enhances the expression of angiogenic factors in skeletal muscle cells of diabetic HLI mice. These angiogenic factors in turn trigger proliferation and migration potentials of blood-vessels forming cells, and subsequently promotes therapeutic angiogenesis in diabetic HLI model mice.